Keyphrases
Advanced Hepatocellular Carcinoma
100%
Aminotransferase Elevation
25%
Angiogenic Factors
25%
Asthenia
25%
Bevacizumab
100%
Bevacizumab Therapy
100%
Cell Cytokines
25%
Circulating Endothelial Cells
100%
Clinical Value
25%
Confidence Interval
25%
Cytokine Factors
25%
Disease Control Rate
25%
Efficacy Biomarkers
100%
Endothelial Cell Count
25%
Hepatocellular Carcinoma
25%
Interleukin-6
25%
Interleukin-6 Levels
25%
Interleukin-8
75%
Metastasis
25%
Neoangiogenesis
25%
Objective Response Rate
50%
Overall Survival Time
25%
Partial Response
25%
Phase II Trial
25%
Placental Growth Factor (PlGF)
25%
Plasma Cytokines
25%
Potential Biomarkers
25%
Progression-free Survival
25%
Safety Biomarkers
25%
Safety Efficacy
25%
Safety Potential
25%
Safety Self-efficacy
100%
Soluble Vascular Endothelial Growth Factor receptor-2
25%
Vascular Endothelial Growth Factor
25%
Vascular Tumor
25%
Medicine and Dentistry
Angiogenic Factor
20%
Asthenia
20%
Bevacizumab
100%
Biological Marker
100%
Bleeding
20%
Cell Count
20%
Circulating Endothelial Cell
80%
Cytokine
20%
Disease
20%
Hepatocellular Carcinoma
100%
Interleukin 6
40%
Interleukin 8
60%
Metastatic Carcinoma
20%
Neoplasm
20%
Overall Survival
20%
Phase II Trials
20%
Placental Growth Factor
20%
Progression Free Survival
20%
Survival Time
20%
Transaminase
20%
Vasculotropin A
20%
Vasculotropin Receptor 2
20%
Nursing and Health Professions
Aminotransferase
20%
Angiogenic Factor
20%
Asthenia
20%
Bevacizumab
100%
Biological Marker
100%
Bleeding
20%
Cell Count
20%
Confidence Interval
20%
Disease Control
20%
Interleukin 6
40%
Interleukin 8
60%
Liver Cell Carcinoma
100%
Neoplasm
20%
Overall Survival
20%
Placental Growth Factor
20%
Progression Free Survival
20%
Survival Time
20%
Vasculotropin A
20%
Vasculotropin Receptor 2
20%
Pharmacology, Toxicology and Pharmaceutical Science
Aminotransferase
20%
Angiogenic Factor
20%
Asthenia
20%
Bevacizumab
100%
Biological Marker
100%
Bleeding
20%
Cytokine
20%
Disease
20%
Interleukin 6
40%
Interleukin 8
60%
Liver Cell Carcinoma
100%
Neoplasm
20%
Overall Survival
20%
Phase II Trials
20%
Placental Growth Factor
20%
Progression Free Survival
20%
Survival Time
20%
Vasculotropin A
20%
Vasculotropin Receptor 2
20%
Biochemistry, Genetics and Molecular Biology
Bevacizumab
100%
Cell Count
20%
Cytokine
20%
Interleukin 6
40%
Interleukin 8
60%
Kinase Insert Domain Receptor
20%
Neoangiogenesis
20%
Overall Survival
20%
Phase II Trials
20%
Placental Growth Factor
20%
Progression Free Survival
20%
Survival Time
20%
Transaminase
20%
Vascular Endothelial Growth Factor A
20%